Alembic Pharma Gets USFDA Nod for Heart Failure Drug
By Rediff Money Desk, New Delhi May 30, 2024 16:20
Alembic Pharmaceuticals receives USFDA approval to market a generic medication for heart failure, a therapeutically equivalent version of Novartis's Entresto tablets.

New Delhi, May 30 (PTI) Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a generic medication used to treat certain types of heart failure.
The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Alembic said in a regulatory filing.
The approved product is therapeutically equivalent to Novartis's Entresto tablets.
Sacubitril and Valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in adult patients with chronic heart failure.
It is also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in paediatric patients aged one year and older.
According to IQVIA, Sacubitril and Valsartan tablets have an estimated market size of USD 5.3 billion for twelve months ending March 2024.
Shares of Alembic Pharma on Thursday ended 0.34 per cent down at Rs 942.95 apiece on the BSE.
The company has received final approval from the US Food & Drug Administration (USFDA) for Sacubitril and Valsartan Tablets in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Alembic said in a regulatory filing.
The approved product is therapeutically equivalent to Novartis's Entresto tablets.
Sacubitril and Valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in adult patients with chronic heart failure.
It is also indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in paediatric patients aged one year and older.
According to IQVIA, Sacubitril and Valsartan tablets have an estimated market size of USD 5.3 billion for twelve months ending March 2024.
Shares of Alembic Pharma on Thursday ended 0.34 per cent down at Rs 942.95 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.82 ( -3.29)
- 32307632
- Quadrant Televenture
- 0.50 ( -3.85)
- 22650423
- Srestha Finvest
- 0.66 (+ 1.54)
- 16236668
- Murae Organisor
- 1.94 (+ 4.86)
- 14718049
- Spright Agro
- 7.37 (+ 4.99)
- 14440430
MORE NEWS

EIH Net Profit Jumps 21.26% to Rs 278.83 Cr in Q3
EIH Ltd. reports a strong 21.26% increase in net profit for the December quarter,...

BEML & Goa Shipyard Partner for Maritime &...
BEML and Goa Shipyard Limited have signed an MoU to collaborate on maritime projects,...

Grew Solar to Invest Rs 3,000 Cr in 3GW Solar...
Grew Solar plans to build a 3 GW solar cell and module plant in Madhya Pradesh, with a...